Call to share experiences of integrating radioligand therapy into care

Call to share experiences of integrating radioligand therapy into care

The Health Policy Partnership wants to better understand what actions and initiatives have taken place to improve the delivery of radioligand therapy.
Read More
SPARC-Europe highlights patient experience of radioligand therapy in new video

SPARC-Europe highlights patient experience of radioligand therapy in new video

SPARC-Europe has released a video of patient testimonies to raise awareness of the benefits of radioligand therapy and outline some of the challenges to access.
Read More
New templates to aid application of the Radioligand Therapy Readiness Assessment Framework

New templates to aid application of the Radioligand Therapy Readiness Assessment Framework

The Health Policy Partnership has published a series of templates to support independent applications of the Radioligand Therapy Readiness Assessment Framework.
Read More
ASH 2021 poster focuses on uptake of radioimmunotherapy for lymphoma

ASH 2021 poster focuses on uptake of radioimmunotherapy for lymphoma

The Health Policy Partnership has published a poster at the 63rd annual meeting of the American Society of Hematology (ASH).
Read More
Leading experts join HPP and Avalere to examine readiness for radioligand therapy in the US

Leading experts join HPP and Avalere to examine readiness for radioligand therapy in the US

The Health Policy Partnership (HPP) and Avalere Health recently held a webinar on the use of radioligand therapy and readiness for its future integration in the US.
Read More
HPP launches policy brief at an event coinciding with ESMO 2021

HPP launches policy brief at an event coinciding with ESMO 2021

HPP was thrilled to launch its new policy brief 'Fostering system readiness in cancer care' on 21 September 2021, at an event coinciding with ESMO 2021.
Read More
Achieving system readiness for radioligand therapy in the UK: the event as it happened

Achieving system readiness for radioligand therapy in the UK: the event as it happened

On 9 September, The Health Policy Partnership (HPP) was pleased to host a webinar to launch the UK situation analysis report and policy action blueprint.
Read More
Radioligand Therapy Readiness Assessment Framework launched at event with esteemed speakers

Radioligand Therapy Readiness Assessment Framework launched at event with esteemed speakers

On 9 June 2021, the new Radioligand Therapy Readiness Assessment Framework was launched at an event with a panel of international and multidisciplinary experts.
Read More
New poster on radioligand therapy readiness published at virtual ESMO congress

New poster on radioligand therapy readiness published at virtual ESMO congress

The Health Policy Partnership and Professor Ken Herrmann have published a poster at the virtual European Society for Medical Oncology (ESMO) congress 2020.
Read More
Poster published at ECRD focuses on radioligand therapy in neuroendocrine neoplasms

Poster published at ECRD focuses on radioligand therapy in neuroendocrine neoplasms

The Health Policy Partnership has published a poster at the 10th European Conference on Rare Diseases & Orphan Products (ECRD).
Read More
New poster published at ENETS virtual conference

New poster published at ENETS virtual conference

The Health Policy Partnership presented a poster on radioligand therapy at the European Neuroendocrine Tumor Society (ENETS) conference.
Read More
Radioligand therapy recommendations form part of submission to Europe’s Beating Cancer Plan

Radioligand therapy recommendations form part of submission to Europe’s Beating Cancer Plan

Recommendations from the radioligand therapy policy report have formed the basis of a submission to Europe’s Beating Cancer Plan, addressing the burden of cancer in the EU.
Read More